LB Pharmaceuticals Inc LBRX

Updated: 9 Aug 2026

NASDAQ | Biotech | Biopharmaceuticals and neuropsychiatry

No signal published yet

We already track LB Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow LB Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals and neuropsychiatry
We're already tracking LB Pharmaceuticals Inc — here are the latest events we've registered

Recent News

  • On July 29, 2026, LB Pharmaceuticals announced a $150 million private placement offering of common stock and pre-funded warrants. The capital raised will support the expansion of clinical development for its lead asset LB-102 into additional indications, as well as general corporate needs.

What Firelda Watch includes for LB Pharmaceuticals Inc

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of LB Pharmaceuticals Inc will be delivered in the same format.

Want to follow LB Pharmaceuticals Inc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow LB Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

LB Pharmaceuticals Inc LBRX
LB Pharmaceuticals — follow and we'll monitor it
Follow LB Pharmaceuticals free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.